By Jeff Bater
Jan. 13 — Legal experts say MetLife's decision to divest part of its business will not necessarily cause the largest U.S. life insurer to drop its challenge to a federal oversight body that designated the company systemically important.
MetLife Inc. plans to separate much of its domestic retail business as Chief Executive Officer Steve Kandarian works to shrink the company amid tighter government oversight (08 Banking Daily, 1/13/16). The insurer said it is weighing a possible sale, spinoff or public offering of the operation — a divestiture that would reduce the company's size by around $240 billion in assets.
MetLife was designated as a systemic risk by the Financial Stability Oversight Council (FSOC) in December 2014, and it mounted a court challenge shortly afterward, calling the FSOC's determination arbitrary and capricious, and saying the regulatory body exceeded its authority (191 Banking Daily, 10/2/15).
Lawrence Baxter, a Duke University law school professor, said he doesn't think the announcement to divest affects the legal appeal in and of itself.
“It is conceivable that be presenting a very different risk profile the court might consider the case moot, but only their lawyers would know whether this is planned or even possible,” he said in an e-mail. “It is also possible that there would be less incentive by MetLife to pursue the appeal, though I doubt it because the remainder of the company would still be under the designation until this is reversed by a court or the FSOC does a renewed (de) designation at its next annual consideration.”
John Coffee, a professor at Columbia University Law School, said in an e-mail that MetLife may proceed with its challenge “unless it can get the FSOC to agree that it is no longer a SIFI.”
“The more that Met Life shrinks, the less it looks like a SIFI,” he said. “Although the decision maximizes value for shareholders and its stock has soared today, I suspect that more of the motivation was to escape increased regulatory scrutiny and higher capital requirements.”
Jaret Seiberg, an analyst at Guggenheim Securities, said in a market commentary he thinks regulators see MetLife's move “as proof positive that the SIFI designation process for nonbanks is working as intended.”
The size of an entity is just one factor FSOC considers when designating a nonbank SIFI, along with interconnectedness and substitutability.
Seiberg said he thinks the divestitures plan is sufficient to cause the regulatory body to reconsider the systemically important designation for MetLife as it would entail the divestiture of $240 billion of assets, while adding such a reconsideration is unlikely to occur until after the transaction closes.
Another analyst, Randy Binner of FBR & Co., said in a note that the new entity MetLife plans to divest would have total assets of $240 billion, in contrast to $250 billion of assets at Lincoln National and $215 billion at Principal Group. Neither of those companies has been designated a nonbank SIFI.
In announcing the divestiture, Kandarian said the company's retail business, as part of a SIFI, faces “higher capital requirements that could put it at a significant competitive disadvantage.”
“Even though we are appealing our SIFI designation in court and do not believe any part of MetLife is systemic, this risk of increased capital requirements contributed to our decision to pursue the separation,” he said in the company statement Jan. 12.
MetLife is represented by Eugene Scalia, a partner with Gibson, Dunn & Crutcher LLP in Washington, D.C. Scalia referred questions to MetLife, which declined to comment on the status of the lawsuit.
— With assistance by Rob Tricchinelli
To contact the reporter on this story: Jeff Bater in Washington at email@example.com
To contact the editor responsible for this story: Seth Stern at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)